Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model

Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Markus MandlerRobert A Rissman

Abstract

Immunotherapeutic approaches targeting amyloid β (Aβ) protein and tau in Alzheimer's disease and α-synuclein (α-syn) in Parkinson's disease are being developed for treating dementia with Lewy bodies. However, it is unknown if single or combined immunotherapies targeting Aβ and/or α-syn may be effective. Amyloid precursor protein/α-syn tg mice were immunized with AFFITOPEs® (AFF) peptides specific to Aβ (AD02) or α-syn (PD-AFF1) and the combination. AD02 more effectively reduced Aβ and pTau burden; however, the combination exhibited some additive effects. Both AD02 and PD-AFF1 effectively reduced α-syn, ameliorated degeneration of pyramidal neurons, and reduced neuroinflammation. PD-AFF1 more effectively ameliorated cholinergic and dopaminergic fiber loss; the combined immunization displayed additive effects. AD02 more effectively improved buried pellet test behavior, whereas PD-AFF1 more effectively improved horizontal beam test; the combined immunization displayed additive effects. Specific active immunotherapy targeting Aβ and/or α-syn may be of potential interest for the treatment of dementia with Lewy bodies.

References

Apr 5, 2001·International Journal of Geriatric Psychiatry·M Simard, R van Reekum
Sep 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·E MasliahL Mucke
Apr 26, 2003·Science·Benoit I GiassonVirginia M-Y Lee
Oct 22, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Sheila M FlemingMarie-Françoise Chesselet
Nov 9, 2005·American Journal of Alzheimer's Disease and Other Dementias·Sara M LippaHiroshi Mori
Mar 14, 2007·Neurology·C F LippaUNKNOWN DLB/PDD Working Group
Jul 27, 2007·Acta Neuropathologica·Hanae Nakashima-YasudaJohn Q Trojanowski
Sep 18, 2007·Advanced Drug Delivery Reviews·Edward RockensteinEliezer Masliah
May 15, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Masashi KitazawaFrank M LaFerla
Jun 16, 2009·Neurobiology of Disease·Cassia R OverkElliott J Mufson
Oct 30, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Brian SpencerEliezer Masliah
May 7, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Kiren UbhiEliezer Masliah
May 28, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Lani K ClintonFrank M LaFerla
Oct 29, 2010·Human Vaccines·Achim SchneebergerWalter Schmidt
Jul 23, 2011·PloS One·Evangelia EmmanouilidouKostas Vekrellis
May 23, 2012·Neurotoxicity Research·Shohreh MajdWeiping Gai
Jul 28, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Megan E LarsonSylvain E Lesné
Sep 28, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Eun-Jin BaeSeung-Jae Lee
Dec 13, 2012·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Mustafa BalkayaMatthias Endres
Dec 21, 2012·Nature Reviews. Neuroscience·Hilal A LashuelEliezer Masliah
Feb 7, 2013·Pharmacology & Therapeutics·Elvira Valera, Eliezer Masliah
Aug 1, 2013·Nature Reviews. Neuroscience·David J IrwinJohn Q Trojanowski
Nov 15, 2013·Journal of Neuropathology and Experimental Neurology·Martí Colom-CadenaAlberto Lleó
Jan 28, 2014·Biochemical Pharmacology·Cassia R Overk, Eliezer Masliah
May 24, 2014·Neurobiology of Disease·Veronica LindströmMartin Ingelsson

❮ Previous
Next ❯

Citations

Jan 15, 2020·Expert Opinion on Pharmacotherapy·Kurt A Jellinger
Apr 30, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Somin KwonEliezer Masliah
Nov 7, 2019·IUBMB Life·Francesca LonghenaArianna Bellucci
Oct 7, 2020·Expert Opinion on Pharmacotherapy·Francesco PanzaBruno P Imbimbo
Feb 14, 2021·Journal of Alzheimer's Disease : JAD·Wim Hendricus QuintThomas Vogels
Jul 3, 2021·Nature Reviews. Disease Primers·Dag AarslandDaniel Weintraub

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.